{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-025935","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.762949+00:00","generated_at":"2026-05-17T15:33:39.456954+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Catheter Precision Q2 revenue up 128% YoY to $212K; net loss $5.4M with $3.2M non-cash","bullets":["Revenue $212K for Q2 2025 vs $93K in Q2 2024, 128% increase; sequential growth 48%.","Net loss $5.4M for Q2 includes $3.2M non-cash charges; cash $838K at June 30.","Received CE Mark for LockeT product; European sales expected to start in Q3 2025.","Completed acquisition of Cardionomic heart failure assets via 82%-owned subsidiary Cardionomix.","Formed Kardionav JV for implant-based software to locate ventricular tachycardia ablation sites."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-025935","json":"https://secwatch.observer/filing/0001437749-25-025935.json","markdown":"https://secwatch.observer/filing/0001437749-25-025935.md","text":"https://secwatch.observer/filing/0001437749-25-025935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925025935/0001437749-25-025935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000143774925025935/vtak20250811_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:33:39.456954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}